Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales

byiShook Opinion
Nov 5, 2024 - 11:30

Share

Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations. The post Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales appeared first on Investor's Business Daily.

Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.

The post Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales appeared first on Investor's Business Daily.